Media headlines about Aduro BioTech (NASDAQ:ADRO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aduro BioTech earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.2537881103143 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Aduro BioTech (NASDAQ:ADRO) traded up $0.30 on Friday, hitting $6.45. The stock had a trading volume of 692,396 shares, compared to its average volume of 497,151. The firm has a market cap of $475.42, a price-to-earnings ratio of -5.12 and a beta of 2.75. Aduro BioTech has a 12 month low of $5.82 and a 12 month high of $14.05.

ADRO has been the topic of several recent research reports. BidaskClub upgraded Aduro BioTech from a “strong sell” rating to a “sell” rating in a research report on Tuesday, January 23rd. Oppenheimer set a $15.00 price objective on Aduro BioTech and gave the stock a “buy” rating in a research report on Monday, December 11th. HC Wainwright lowered their price objective on Aduro BioTech from $18.00 to $9.50 and set a “buy” rating on the stock in a research report on Wednesday, December 13th. ValuEngine cut Aduro BioTech from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Canaccord Genuity set a $30.00 price objective on Aduro BioTech and gave the stock a “buy” rating in a research report on Thursday, December 14th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $16.33.

In other news, insider Elsas Andrea Van sold 6,874 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.48, for a total transaction of $44,543.52. Following the sale, the insider now directly owns 216,669 shares of the company’s stock, valued at approximately $1,404,015.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Dirk G. Brockstedt sold 65,223 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $8.11, for a total value of $528,958.53. Following the sale, the executive vice president now directly owns 137,826 shares in the company, valued at $1,117,768.86. The disclosure for this sale can be found here. Over the last three months, insiders have sold 102,930 shares of company stock worth $812,690. 6.60% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Aduro BioTech (ADRO) Getting Somewhat Favorable News Coverage, Report Shows” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with's FREE daily email newsletter.